Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Natera Inc (NQ: NTRA )

68.62 USD +3.74 (+5.76%)
Official Closing Price Updated: 4:45 PM EDT, Sep 25, 2020 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,986,700
Open 65.18
Bid (Size) 65.03 (10)
Ask (Size) 71.58 (1)
Prev. Close 64.88
Today's Range 64.42 - 71.08
52wk Range 16.87 - 71.08
Shares Outstanding 54,512,645
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Medicare Issues Draft Local Coverage Determination for Signatera™ in Immunotherapy Response Monitoring
Proposes expanded coverage of the Signatera minimal residual disease (MRD) test in a broad range of solid tumor types and indications including immunotherapy (IO) monitoring 
From PR Newswire
Natera to Present New Gastrointestinal Cancer Data at the ESMO Annual Meeting
1 oral and 3 poster presentations demonstrate effectiveness of Signatera™ in stage IV oligometastatic colorectal cancer (CRC), stage I-III CRC, and esophageal adenocarcinomas 
From PR Newswire

Performance

YTD
+106.13%
+106.13%
1 Month
+5.85%
+5.85%
3 Month
+49.50%
+49.50%
6 Month
+169.52%
+169.52%
1 Year
+109.98%
+109.98%

More News

Read More
Natera Launches Initiative to Transform the Management of Cancer Patients in Organ Transplantation
From PR Newswire
Natera's Signatera™ MRD Test Receives a Final Coverage Decision from Noridian in Colorectal Cancer
From PR Newswire
Natera Announces Pricing of Follow-On Offering
From PR Newswire
Natera to Present at the Morgan Stanley 18th Annual Global Healthcare Conference
From PR Newswire
Natera Launches Proposed Follow-On Offering
From PR Newswire
Natera Receives Final Medicare Coverage for its Signatera™ MRD Test in Stage II-III Colorectal Cancer
From PR Newswire
SMART Study Data for Aneuploidy and 22q Unblinded
From PR Newswire
Study Shows Clinical Utility of the Prospera™ Test in Nephrology Practice
From PR Newswire
Natera Announces Collaboration with Massachusetts General Hospital for a Prospective Randomized Clinical Trial in Early Stage Breast Cancer
From PR Newswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.